Uncategorized
Custom sequence testing may accurately define glaucoma severity
CORONADO, Calif. — Custom sequence testing for relative afferent pupillary defect may objectively quantify disease severity compared with standard testing sequence, according to a presentation here.In a poster presented at the American Glaucoma Society meeting, Alice Williams, MD, and colleagues examined 49 patients with glaucoma who underwent relative afferent pupillary defect testing with the Konan RAPDx pupillograph using standard and custom testing sequences.